Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | GRK6 | P43250 | 1/20 | 0.45 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6454836 | 0.81 | GRK6 (0.48) | MAPTLMNAMEN1KMT2AGRK6 | |
| SCHEMBL6454632 | 0.81 | ALDH1A1 (0.53) | MAPTMEN1KMT2AIDO1GRK6 | |
| SCHEMBL6452160 | 0.80 | RAB9A (0.62) | MAPTLMNAMEN1KMT2AIDO1 | |
| SCHEMBL6461023 | 0.80 | NPC1 (0.65) | MAPTKEAP1NFE2L2RAB9ANPC1 | |
| SCHEMBL6454205 | 0.78 | NR1H2 (0.56) | GRK6RAB9ANPC1SMN1; SMN2ABCG2 | |
| SCHEMBL6451202 | 0.77 | MAPT (0.53) | MAPTLMNAMEN1KMT2AIDO1 | |
| SCHEMBL17279705 | 0.76 | MAPT (0.77) | MAPTLMNAMEN1KMT2AIDO1 | |
| SCHEMBL6449759 | 0.76 | MAPT (0.52) | MAPTLMNAMEN1KMT2AIDO1 | |
| SCHEMBL6450407 | 0.75 | FEN1 (0.43) | LMNASCN2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6451531 | 0.75 | MAPT (0.60) | MAPTLMNAMEN1KMT2AIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | MAPT 2805/4885LMNA 2406/4885MEN1 3473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.